H&N Cancer; Survivorship and Late Effects

Head and Neck Neoplasms Clinical Trial

Official title:

Survivorship and Late Effects in Head and Neck Cancer Survivors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04758026
• Other study ID #: 2018-21
• Status: Completed
• Start date: October 10, 2018
• Est. completion date: October 10, 2020

Study information

• Verified date: December 2023
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A cross-sectional study on late effects after modern treatment in long-term survivors of head and neck cancer (HNC). Participants fill in questionnaires and participate at a one day visit at the hospital including blood sample with biomarkers, clinical examination, audiometry, oral radiological examination and oral examination. Data on patients' medical history collected from medical records including radiology images and digital radiotherapy plans.This will allow adjustments of treatment planning and improved treatment decisions for patients at risk, and improve information and follow up for future patients.

Description:

The purpose of this study is to provide knowledge on late effects and mortality risk after modern treatment in long-term survivors of head and neck cancer (HNC). This will allow adjustments of treatment planning and improved treatment decisions for patients at risk, and improve information and follow up for future patients. For head and neck cancer (HNC) survivors of today, with the rising proportion of HPV induced cancer and with improved modern treatment, the late effects and mortality risk has changed compared to survivors previous decades. The investigators will assess the prevalence and severity of a broad range of late effects and identify associated risk factors for the following late effects; - Chronic fatigue - Hearing loss and tinnitus - Oral late effects, including taste and smell disturbances and osteoradionecrosis - Dysphagia and malnutrition - Body image, intimacy and endocrine dysfunction In addition,possible biological explanatory mechanisms for fatigue and possibly other selected late effects will be explored. Data will be compared to age and gender matched reference data for those where this is available. Design: a cross-sectional study Assessments: Patient-reported questionnaires, blood sample with biomarkers, clinical examination, audiometry, oral radiological examination and oral examination. Data on patients' medical history collected from medical records including radiology images and digital radiotherapy plans.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 265
• Est. completion date: October 10, 2020
• Est. primary completion date: October 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically verified invasive carcinoma of the head and neck region; ICD10: C01, C02.0 - C02.9; C03.0 - C03.9; C04.0 - C04.9; C05.0 - C05.9; C06.0
• C06.9; C07; C08.0 - C08.9; C09.0 - C09.9; C10.0 - C10.9; C11.0 - C11.9; C12; C13.0 - C13.9; C14.0 - C14.9; C30; C31.0 - C31.9; C32.0 - C32.9, C77.0
• Diagnosed 2006- 2012
• Ability to understand and respond to the questionnaires
• Ability to attend the clinical examination
• Informed consent received

Exclusion Criteria:

• Unwillingness to answer HRQL questionnaires
• Patients under ongoing treatment for secondary cancer or relapse at the time of the survey

Related Conditions & MeSH terms

• Head and Neck Neoplasms
• Survivorship

Locations

Country	Name	City	State
Norway	Oslo University Hospital	Oslo

Sponsors (2)

Lead Sponsor	Collaborator
Oslo University Hospital	University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of late effects after head and neck cancer treatment measured with patient-reported questionnaires	Assess prevalence of fatigue, dysphagia, xerostomia, hearing problems, oral health, body image and intimacy in surivors of head and neck cancer more than 5 years after treatment. Patients filled in a set of patient-reported questionnaires: 1) EORTC core quality of life questionnaire, the EORTC QLQ-C30 version 3, 2) EORTC disease specific module, the EORTC QLQ-H&N35 3) The Fatigue Questionnaire, 4) The scale for chemotherapy induced neurotoxicity (SCIN), 5) EORTC-QLQ-OH15, 6) Body image scale.	June 2022
Secondary	Risk factors for late effects after head and neck cancer treatement	to explore associated risk factors for fatigue, dysphagia, xerostomia, hearing problems, oral health in surivors of head and neck cancer more than 5 years after treatment	June 2022